Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors

Osman H. M., Tuncbilek M.

CURRENT MEDICINAL CHEMISTRY, cilt.29, sa.15, ss.2602-2616, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 29 Sayı: 15
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2174/0929867328666210914121324
  • Dergi Adı: CURRENT MEDICINAL CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2602-2616
  • Anahtar Kelimeler: Entrectinib, indazol benzamide, Trk ABC, ALK, ROS1 inhibitor, NTRK fusion-positive tumors, ALK INHIBITOR, TRK INHIBITOR, PAN-TRK, ACQUIRED-RESISTANCE, INTEGRATED ANALYSIS, ANTITUMOR-ACTIVITY, POTENT INHIBITOR, OPEN-LABEL, ROS1, CANCER
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: Entrectinib is a highly potent ATP-competitive and selective inhibitor of tyrosine kinases - Trk A B C, ALK, and ROS1. It was developed by Roche and initially approved in Japan in 2019 to treat pediatric and adult patients with NTRK fusion-positive, recurrent, or advanced solid tumors. In August 2019, entrectinib received accelerated approval by the U.S FDA for this indication. It is also the first FDA-approved drug designed to target both NTRK and ROS1.